What is Biomedical Engineering?
Biomedical engineering is a multidisciplinary field that combines principles of engineering and medical sciences to design and develop solutions for healthcare. It focuses on applying engineering principles to understand, diagnose, and treat medical conditions. Biomedical engineers work on a wide range of projects, including medical device design, prosthetics, imaging technologies, tissue engineering, and healthcare informatics. Their work often involves collaborating with healthcare professionals, conducting research, and developing innovative technologies to improve patient care and enhance the overall effectiveness of the healthcare system.
Organ on a Chip Technology
A microfluidic cell culture device with constantly perfused compartments is known as an organ on a chip. This chip creates a narrow route for blood and airways in organs such as the lungs, stomach, liver, and heart. By using traditional 2D and 3D culture systems, such devices can develop different levels of tissue and organ functionality. Organ-on-a-chip can be used for disease modeling, patient stratification, phenotypic screening, and other forms of life-changing research.
Over the projected period of 2022-2027, the global organ on a chip market is expected to rise at a CAGR of 30%.
The Top Organ on a Chip Companies
Here are 20 of the most innovative organ-on-a-chip companies in the world:
CEO - Jim Corbett
Located in the US, Emulate has developed an automated bio-emulation platform for studying neuronal and vascular endothelial cells in a micro-engineered living environment. This platform is a new living system that mimics human biology to better understand how diseases, medicines, chemicals, and foods affect human health by combining micro-engineering with living human cells.
CEO - Jan Lichtenberg
Located in Switzerland, InSphero provides 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology for in vitro testing that delivers biologically relevant insights. InSphero's technology aids in the early detection of pharmaceuticals and toxic risks, allowing the pharmaceutical and biotechnology sectors to limit the use of animals in testing.
CEO - Guilhem Velvé Casquillas
Located in Paris, Elveflow sells fluid control tools for microsystems and molecular biology reagents for detecting unknown mutations, giving industrial research labs and clinical diagnostic centers complete control over microfluidic systems.
CEO & Co-Founder - Paul Vulto
Located in the Netherlands, Mimetas creates organ-on-a-chip products for compound testing, screening, and basic research. Mimetas's product allows clinicians to test compounds in high-throughput on miniaturized organ models using 3D cell culture with continuous perfusion.
Co-Founder - Jian Shi
Located in France, MesoBioTech provides integrative solutions for research, teaching, and large-scale applications. Their focus is sophisticated stem cell technologies based on creating artificial basement membranes consisting of a monolayer of gelatin nanofibers and functional proteins (culture patch). The patches might then be reversibly merged with microfluidic devices to produce organ-on-a-chip and microphysiological systems, which are crucial for disease modeling, toxicity testing, drug screening, and regenerative medicine research.
Co-Founder - Dustin Dopsa
Located in the Netherlands, chiron is a company developing leading on-chip biotechnologies with a particular focus on platforms that apply physiological biomechanical strains to 3D cultures. The novel technology is ideally suited for musculoskeletal organ-chip models, such as cartilage, which is where the company specializes—recapitulating tissues within the joints and tackling diseases like osteoarthritis and rheumatoid arthritis. chiron collaborates openly with academics and research institutes and provides customer-service focused research services to the pharmaceutical industry.
CEO - Lowry Curley
Located in the US, AxoSim has developed a neurological drug discovery platform that focuses on preclinical pharmaceutical development and therapeutic development. The platform provides an alternative to costly animal testing and ineffective 2D models by simulating the in vivo nervous system in an in vitro setting.
CEO - Misti Ushio
Located in the US, TARA Biosystems has developed a biotech platform that uses predictive cardiac tissue models to leverage human biology and data to transform cardiac medication discovery. The platform uses stem cells to create heart cells, allowing for the measurement of changes in human cardiac function without the need for human testing. This enables for the development of medicines.
CEO - Jeremy Cramer
Located in France, Cherry Biotech focuses on the development of a new generation of cell environment control that is suitable for organs-on-a-chip. Using their patented microfluidic technique, they can culture and replicate any human organ in a physiological and pathological state.
CTO - Ana Rita Ribeiro
Located in France, 4Dcell has developed a revolutionary 3D cell culture system that simulates in vivo circumstances and, eventually, organ function though comprehensive regulation of the cell microenvironment.This system allows for the acquisition of more physiologically appropriate readouts.
President & CEO - Thomas Neumann
Located in the US, Nortis has developed in-vitro technology that aids in the discovery of new medicines. The company's technology enables physicians to speed up study and scientific investigation by allowing them to create human tissues and organs in vitro in a disposable chip-like device.
CEO - Jeff Gatz
Located in the US, BioIVT has the OrganDOT platform, which combines high-quality primary cultures with a stable air-liquid interface to recreate tissue architecture and functions. This technology has been used to construct established models such as pancreatic islets and lung airway epithelium.
CEO & Scientific Director - Nina Hobi
Located in Switzerland, AlveoliX has developed in-vitro lung products for drug testing. The company's products aid in simulating the biophysical characteristics of lungs, predicting the effects of respiratory drug candidates in humans, and reducing the number of candidates to be tested in clinical trials.
CEO - Reyk Horland
Located in Germany, TissUse has developed a unique "Multi-Organ-Chip" platform that uses human tissues to deliver exceptional preclinical knowledge on a systemic level. This multi-organ-on-chip has four organs on the same chip, as well as a variety of organs-on-chips. It is currently working on a new human-on-a-chip with ten organs.
CEO - Rosa Monge Prieto
Located in Spain, BEOnchip creates innovative cell culture equipment in order to make the cells' habitat as biomimetic as possible. Their goal is to use this technology to make drug testing more viable, expedite the development of new treatments, and lower the cost of drug development.treatments.
CEO - Paola Occhetta
Located in Italy, BiomimX an organ-on-chip firm that creates predictive models of human organs and diseases in order to test novel medications.
CEO - Einat Zisman
Located in Israel, Tissue Dynamics is an AI-driven Bionic Human Organoids Drug Development firm with Human-Relevant Disease Models and a Sensor-Illuminated Drug Discovery and Development Platform.
CEO - Michael Biron
Located in North Carolina, Altis Biosystems develops a stem cell platform for regenerating the human intestinal epithelium. RepliGut is a stem and differentiated cell organ-on-a-chip technology with a patent-pending biomimetic framework enabling the customisation of the small intestine and colon based on geographic specificity from various donors.
CEO - Nikolas Gaio
Located in the Netherlands, Bi/ond creates customizable organ-on-a-chip solutions for in vitro testing. Their product inCHIPit has an open well for tissues, a porous membrane, and a bottom compartment for microchannels delivering oxygen and nutrients. This allows for the longitudinal assessment of organoid tissue cultures utilizing microscope-compatible instruments.
CEO & Co-Founder - Thibault Honegger
Located in France, Netri develops brain-on-a-chip technology for use in neuroscience. The startup's microfluidics-based device, Neurofluidics, reconstructs the brain's structural and functional network in vitro.
CEO - Robert Freedman
Located in the US, Hurel develops advanced micro-liver tissue specializing in microfluidic cell-based test systems. The company's micro-liver tissue has metabolic competency and cell culture endurance, allowing clinicians to replicate pharmacokinetic interactions among numerous tissues and organs.
Advance Your Organ on a Chip Company with Scispot OS
Scispot is on a mission to empower bioentrepreneurs and make workflow automation possible for every life science lab on this planet. To learn more about Scispot and its no-code digital toolkit for lab digitalization and automation, book a demo here.
.jpg)
